Pfizer Inc. (PFE)
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
Pfizer PFE is scheduled to report its first-quarter 2026 results on May 5, with investor focus firmly on its oncology portfolio, which contributes roughly 27% of total revenues. Leading cancer therapies in its lineup include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi, as well as antibody-drug conjugates like Padcev acquired through Seagen.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Pfizer (PFE) reached $27.34 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.
Trellus Health shares jump 39% on Pfizer deal renewal
Trellus Health PLC (AIM:TRLS), the digital chronic disease management platform, surged 39% to 0.28p after the company announced it had renewed its licensing agreement with Pfizer. Under the renewed deal, Pfizer will continue to license Trellus Health's patient-support educational content for use in its inflammatory bowel disease (IBD) digital application.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Pfizer PFE is one of the largest and most successful drugmakers in oncology with an established presence in breast, genitourinary, thoracic, gastrointestinal cancer and blood cancers. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) concluded the recent trading session at $27.1, signifying a -2.62% move from its prior day's close.
Why Pfizer (PFE) Outpaced the Stock Market Today
In the most recent trading session, Pfizer (PFE) closed at $28.55, indicating a +1.67% shift from the previous trading day.
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
Pfizer's PFE stock has been trading steadily above its 50-day and 200-day simple moving averages (SMAs) since early January, signaling sustained investor confidence. The stock is also up about 12.8% so far in 2026.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer: Why Wall Street Habitually Overestimates Target Price
Pfizer Inc. (PFE) currently receives a buy rating from Wall Street, but I believe the rating is overoptimistic. Political uncertainties around 'TrumpRx' and 'Most-Favored-Nation' drug pricing models continue to threaten PFE's margins and valuation outlook. PFE's FWD P/E of 9.3x appears attractive on the surface, but is actually not once the multi-year earnings decline risks are factored in.
Why Pfizer Remains A Strong Buy In 2026
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of Talzenna rose 81.5% year-on-year to $49 million.
Why the Market Dipped But Pfizer (PFE) Gained Today
In the closing of the recent trading day, Pfizer (PFE) stood at $27.57, denoting a +1.06% move from the preceding trading day.
